Although the data from bluebird bio so far looks good, investors have been ratcheting back exposure to the company to reflect what's emerging to be a very competitive marketplace.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,